

**CLEOPATRA HOSPITAL COMPANY “S.A.E.”  
AND ITS SUBSIDIARIES**

**LIMITED REVIEW REPORT  
AND THE INTERIM CONDENSED CONSOLIDATED  
FINANCIAL STATEMENTS  
FOR THE THREE MONTHS PERIOD ENDED  
31 MARCH 2026**

# CLEOPATRA HOSPITAL COMPANY “S.A.E.” AND ITS SUBSIDIARIES

## Interim condensed consolidated financial statements For the three months period ended 31 March 2026

---

<b>Index</b>	<b>Page</b>
Limited review report	1 – 2
Interim condensed consolidated statement of financial position	3
Interim condensed consolidated statement of profit or loss	4
Interim condensed consolidated statement of comprehensive income	5
Interim condensed consolidated statement of changes in equity	6
Interim condensed consolidated statement of cash flows	7
Notes to the interim condensed consolidated financial statements	8 – 29

## *Limited Review Report on the Interim Financial Statements*

*To the Board of Directors of Cleopatra Hospital Company (S.A.E.)*

### *Introduction*

We conducted our limited review on the accompanying interim condensed consolidated financial position of Cleopatra Hospital Company (S.A.E.) and its subsidiaries (the "Group") as at 31 March 2026 and the related interim condensed consolidated statements of profit or loss, comprehensive income, changes in equity and cash flows for the three months period then ended. The management is responsible for the preparation and fair presentation of these interim condensed consolidated financial statements in accordance with the Egyptian Accounting Standard No. (30) "Interim Financial Reporting". Our responsibility is limited to express a conclusion on these interim condensed consolidated financial statements based on our limited review.

### *Scope of the limited review*

We conducted our limited review in accordance with the Egyptian Standard on Limited Review Engagements (2410), "Limited Review of Interim Financial Statements Performed by the Auditor of the Entity". A limited review of the interim condensed consolidated financial statements consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other limited review procedures. A limited review is substantially less in scope than an audit conducted in accordance with the Egyptian Standards on Auditing and consequently does not enable us to obtain an assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion on these interim condensed consolidated financial statements.

### *Conclusion*

Based on our limited review, nothing has come to our attention which causes us to believe that the accompanying interim condensed consolidated financial statements are not prepared, in all material respects in accordance with the Egyptian Accounting Standard No. (30) "Interim Financial Reporting".

  
Mohamed Elsawaf  
R.A.A. 39521  
F.R.A. 419  
4 June 2026  
Cairo





CLEOPATRA HOSPITAL COMPANY "S.A.E." AND ITS SUBSIDIARIES

Interim condensed consolidated statement of financial position – At 31 March 2026

(All amounts are shown in Egyptian Pounds)	Note	31 March 2026	31 December 2025
<b>Assets</b>			
<b>Non-current assets</b>			
Fixed assets	4	7,391,456,655	7,072,923,092
Right-of-use assets	5	124,997,333	132,920,919
Goodwill		355,192,334	355,192,334
Other intangible assets		47,457,936	47,975,257
Investments in associates		18,585,651	18,585,651
Advance Payments / Revenue Share	6	241,603,960	250,336,106
<b>Total non-current assets</b>		<b>8,179,293,869</b>	<b>7,877,933,359</b>
<b>Current assets</b>			
Inventories	7	317,919,654	281,335,004
Trade and other receivables	8	1,445,452,787	1,241,456,016
Debtors and other debit balances	9	292,443,282	292,992,065
Cash and cash equivalent	10	749,579,244	547,542,841
<b>Total current assets</b>		<b>2,805,394,967</b>	<b>2,363,325,926</b>
<b>Total assets</b>		<b>10,984,688,836</b>	<b>10,241,259,285</b>
<b>Equity and liabilities</b>			
<b>Equity</b>			
Share capital		724,725,042	724,725,042
Retained earnings		2,823,097,586	2,705,002,786
Employees stock ownership Plan		49,049,245	32,699,496
Reserves		159,910,009	159,910,009
<b>Equity attributable to the Company's owners</b>		<b>3,756,781,882</b>	<b>3,622,337,333</b>
Non-controlling interests	11	452,842,000	418,028,210
<b>Net equity</b>		<b>4,209,623,882</b>	<b>4,040,365,543</b>
<b>Liabilities</b>			
<b>Non-Current liabilities</b>			
Lease liabilities	14	109,705,892	122,201,397
Deferred tax liabilities		68,313,314	83,625,726
Loans	12	2,771,695,990	2,684,749,460
<b>Total non-current liabilities</b>		<b>2,949,715,196</b>	<b>2,890,576,583</b>
<b>Current liabilities</b>			
Banks overdraft		513,617,643	391,325,194
Loans	12	457,951,145	451,063,593
Provisions		63,131,587	81,404,628
Trade and other payables	13	2,225,697,791	1,932,432,352
Other liabilities		42,490,000	42,490,000
Lease liabilities	14	60,687,217	53,418,784
Employees stock ownership Plan		95,931,762	73,961,551
Current income tax liabilities		365,842,613	284,221,057
<b>Total current liabilities</b>		<b>3,825,349,758</b>	<b>3,310,317,159</b>
<b>Total liabilities</b>		<b>6,775,064,954</b>	<b>6,200,893,742</b>
<b>Total equity and liabilities</b>		<b>10,984,688,836</b>	<b>10,241,259,285</b>

The accompanying notes from 1 to 21 are integral part of these interim condensed consolidated financial statements.

  
Mr. Amr Al Rashid  
Chief Financial Officer

  
Dr. Ahmed Ezz El Dein Mahmoud  
CEO and Managing Director

  
Mr. Ahmed Adel Badr El dien  
Non-Executive Chairman of the  
Board of Directors



4 June 2026  
Limited review report is attached.

CLEOPATRA HOSPITAL COMPANY “S.A.E.” AND ITS SUBSIDIARIES

Interim condensed consolidated statement of profit or loss  
For the three months period ended 31 March 2026

(All amounts in Egyptian Pounds)	Note	31 March 2026	31 March 2025
Revenue	15	1,972,518,001	1,618,657,555
<b>Deduct:</b>			
Cost of revenue	16	(1,327,929,734)	(1,004,393,085)
<b>Gross profit</b>		<b>644,588,267</b>	<b>614,264,470</b>
<b>Add;</b>			
General and administrative expenses	17	(327,049,341)	(228,321,120)
Net impairment losses on financial assets	18	(31,410,667)	(34,381,624)
Other expenses		(7,341,797)	(2,838,626)
<b>Operating profit</b>		<b>278,786,462</b>	<b>348,723,100</b>
Finance income		11,432,241	15,962,724
Finance expenses		(71,000,964)	(43,158,553)
Consulting expenses for acquisition activities		-	(330,000)
<b>Profit for the period before income tax</b>		<b>219,217,739</b>	<b>321,197,271</b>
Current tax		(81,621,556)	(78,277,451)
Deferred tax		15,312,407	(10,630,550)
<b>Net profit for the period</b>		<b>152,908,590</b>	<b>232,289,270</b>
<b>Profit is attributable to</b>			
Owners of the Parent Company		118,094,800	200,580,474
Non-controlling interest		34,813,790	31,708,796
		<b>152,908,590</b>	<b>232,289,270</b>
<b>Earnings per share (basic/ diluted)</b>	19	<b>0.08</b>	<b>0.14</b>

The accompanying notes from 1 to 21 are integral part of these interim condensed consolidated financial statements.

## CLEOPATRA HOSPITAL COMPANY “S.A.E.” AND ITS SUBSIDIARIES

### Interim condensed consolidated statement of comprehensive income For the three months period ended 31 March 2026

(All amounts in Egyptian Pounds)	<u>31 March 2026</u>	<u>31 March 2025</u>
Profit for the period	152,908,590	232,289,270
Other comprehensive income items	-	-
<b>Comprehensive income for the period</b>	<b><u>152,908,590</u></b>	<b><u>232,289,270</u></b>
<b>Profit is attributable to:</b>		
Owners of the Parent Company	118,094,800	200,580,474
Non-controlling interest	34,813,790	31,708,796
	<b><u>152,908,590</u></b>	<b><u>232,289,270</u></b>

The accompanying notes from 1 to 21 are integral part of these interim condensed consolidated financial statements.

**CLEOPATRA HOSPITAL COMPANY "S.A.E." AND ITS SUBSIDIARIES**

**Interim condensed consolidated statement of changes in equity  
For the three months period ended 31 March 2026**

(All amounts in Egyptian Pounds)	Share capital	Treasury Shares	Reserve	Retained Earnings	Employees stock ownership plan	Total Shareholders' equity of the parent company	Non-controlling interest	Total equity
<b>Balance at 1 January 2025</b>	722,717,101	(5,589,873)	97,276,022	2,048,718,617	36,466,935	2,899,588,802	278,208,598	3,177,797,400
Employees Stock Ownership Plan value	-	-	-	-	30,000,000	30,000,000	-	30,000,000
Total comprehensive income for the period	-	-	-	200,580,474	-	200,580,474	31,708,796	232,289,270
<b>Balance at 31 March 2025</b>	<b>722,717,101</b>	<b>(5,589,873)</b>	<b>97,276,022</b>	<b>2,249,299,091</b>	<b>66,466,935</b>	<b>3,130,169,276</b>	<b>309,917,394</b>	<b>3,440,086,670</b>
<b>Balance at 1 January 2026</b>	724,725,042	-	159,910,009	2,705,002,786	32,699,496	3,622,337,333	418,028,210	4,040,365,543
Employees Stock Ownership Plan value	-	-	-	-	16,349,749	16,349,749	-	16,349,749
Total comprehensive income for the period	-	-	-	118,094,800	-	118,094,800	34,813,790	152,908,590
<b>Balance at 31 March 2026</b>	<b>724,725,042</b>	<b>-</b>	<b>159,910,009</b>	<b>2,823,097,586</b>	<b>49,049,245</b>	<b>3,756,781,882</b>	<b>452,842,000</b>	<b>4,209,623,882</b>

The accompanying notes from 1 to 21 are integral part of these interim condensed consolidated financial statements.

CLEOPATRA HOSPITAL COMPANY “S.A.E.” AND ITS SUBSIDIARIES

**Interim condensed consolidated statement of cash flows**  
**For the three months period ended 31 March 2026**

(All amounts in Egyptian Pounds)	Note	31 March 2026	31 March 2025
<b>Cash flows from operating activities</b>			
Profit before tax		219,217,739	321,197,271
<b>Adjustments to settle net profit with cash flow from operating activities:</b>			
Fixed Assets depreciation	4	118,392,706	50,176,378
Right of use depreciation	5	8,335,211	8,665,231
Advance Payments / Revenue Share amortization	6	8,732,146	-
Gain on disposal of fixed assets		(82,928)	(1,111,837)
Financial assets impairment	18	31,410,671	34,381,624
Inventory impairment	7	3,013,276	243,581
Provisions		9,271,770	6,608,623
Interest and commission - Bank's overdraft		61,895,131	36,084,629
Interest and commission - Lease contracts	14	9,105,833	7,073,924
Interest income		(8,264,587)	(14,325,121)
Intangible assets amortization		517,321	517,321
Employees stock ownership plan		38,319,960	30,000,000
<b>Operating cash flows before changing in assets and liabilities</b>		<b>499,864,249</b>	<b>479,511,624</b>
<b>Changes in assets and liabilities</b>			
Changes in inventories		(39,597,926)	(11,610,980)
Changes in trade receivables		(232,524,338)	(157,733,498)
Changes in debtors and other debit balances		548,783	308,300,558
Changes in trade and other payables		328,836,029	(67,079,980)
<b>Change in working capital</b>		<b>557,126,797</b>	<b>551,387,724</b>
Income taxes paid		-	(1,031,695)
Provisions – used		(27,544,811)	(17,861,145)
<b>Net cash flow generated from operating activities</b>		<b>529,581,986</b>	<b>532,494,884</b>
<b>Cash flows from investing activities</b>			
Payments and down payments for the purchase of fixed assets	4	(94,776,411)	(31,083,537)
Payments for Projects under construction	4	(420,936,876)	(607,221,870)
Proceeds from the sale of fixed assets		119,241	1,111,837
Interest received		8,264,587	13,989,779
<b>Net cash flows used in investing activities</b>		<b>(507,329,459)</b>	<b>(623,203,791)</b>
<b>Cash flows from financing activities</b>			
Proceeds from bank's overdraft		122,292,449	28,697,623
Proceeds from loans		93,834,082	331,918,668
Payments for lease liabilities		(14,744,532)	(10,940,934)
Interest and commission paid		(18,715,019)	(36,084,629)
<b>Net cash flows generated from financing activities</b>		<b>182,666,980</b>	<b>313,590,728</b>
<b>Changed in cash and cash equivalents during the period</b>			
Cash and cash equivalents at the beginning of the period		554,583,219	477,812,191
<b>Cash and cash equivalents at the end of the period</b>	10	<b>759,502,726</b>	<b>700,694,012</b>

The accompanying notes from 1 to 21 are integral part of these interim condensed consolidated financial statements.

# CLEOPATRA HOSPITAL COMPANY “S.A.E.” AND ITS SUBSIDIARIES

## Notes to the interim condensed consolidated financial statements For the three months period ended 31 March 2026

(All amounts in the notes are shown in Egyptian Pounds unless otherwise stated)

---

### 1. Introduction

Cleopatra Hospital Company the “parent company” previously (Lasheen and Partners) was established as a limited partnership on 19 July 1979. The decision of the Chairman of Investment Authority No. 4092 of 2005 was issued on 27 June 2005 authorising the conversion of the legal type of Cleopatra Hospital (Lasheen and Partners) from a "limited partnership" into Cleopatra Hospital Company "S.A.E.". The Company was incorporated and is domiciled in the Arab Republic of Egypt. The Company is a public joint stock company and was incorporated in accordance with law No. 95 of 1992.

The company is listed in the Egyptian Stock Exchange.

#### Principal activity.

The Company's purpose is to establish a private hospital to provide advanced modern health and medical services, as well as the medical care of in-patients. The Company may have interest or participate in any manner in companies or other firms which carry on similar activities in Egypt or abroad. The Company may acquire merge or affiliate such entities under the General Authority for Investment.

#### Registered address and place of business.

The Company is located at 39, 41 Cleopatra Street. Heliopolis. Cairo.

#### Presentation currency.

Presentation currency is Egyptian pound.

These interim condensed consolidated financial statements were approved for issue by the Parent Company's Board of Directors on **4 June 2026**.

### 2. Basis of preparation

#### 2.1 Basis of financial statements preparation

The accompanying condensed interim consolidated financial statements have been prepared for the three-month period ended 31 March 2026 in accordance with Egyptian Accounting Standard No. 30 “Interim Financial Reporting.”

These condensed interim consolidated financial statements do not include all the disclosures normally provided in the annual consolidated financial statements and should be read in conjunction with the Group’s annual consolidated financial statements for the year ended 31 December 2025.

The results for the three-month period ended 31 March 2026 are not necessarily indicative of the results that may be expected for the financial year ending 31 December 2026.

The accounting policies applied in the preparation of these condensed interim consolidated financial statements are consistent with those used in the preparation of the annual consolidated financial statements for the year ended 31 December 2025 and the comparative financial periods.

## CLEOPATRA HOSPITAL COMPANY “S.A.E.” AND ITS SUBSIDIARIES

### Notes to the interim condensed consolidated financial statements For the three months period ended 31 March 2026

(All amounts in the notes are shown in Egyptian Pounds unless otherwise stated)

#### 2. Basis of preparation (continued)

##### 2.1 Basis of financial statements preparation (continued)

The interim condensed consolidated financial statements include the financial statements of the following subsidiaries:

	Relationship with Cleopatra Hospital	Country of incorporation	Percentage of ownership 31 March 2026	Percentage of ownership 31 December 2025
Al-Shorouk Hospital Company S.A.E.	Subsidiary	Egypt	99.99%	99.99%
Nile Badrawi Hospital Company S.A.E.	Subsidiary	Egypt	99.99%	99.99%
Cairo Specialised Hospital Company S.A.E.	Subsidiary	Egypt	57.01%	57.01%
CHG for Medical Services Company S.A.E.	Subsidiary	Egypt	20% (Preferred shares)	20% (Preferred shares)
CHG Pharma for Pharmacies Management Company S.A.E.	Subsidiary	Egypt	98%	98%
CHG for hospitals S.A.E.	Subsidiary	Egypt	99.99%	99.99%
Bedaya El Gedida Company for Medical Centers and Hospitals S.A.E.	Subsidiary	Egypt	60%	60%
CHG Sky Hospital S.A.E.	Subsidiary	Egypt	99.99%	99.99%
Cleopatra Heavens Hospital S.A.E.	Subsidiary	Egypt	99.99%	99.99%

##### 2.2 Functional and presentation currency

The functional currency of each of the Group's companies is the currency of the primary economic environment in which the Company operates. The functional and presentation currency of the Company and all of its subsidiaries is the national currency of the Arab Republic of Egypt, the Egyptian pound. The consolidated financial statements are presented in Egyptian pound, which is the Group's presentation currency.

##### 2.3 Use of estimates and judgments

The preparation of interim financial statements requires management to make judgements, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets and liabilities, income, and expense. Actual results may differ from these estimates.

Significant judgments used by management in applying the group's accounting policies and the main sources of estimation uncertainty are the same as those disclosed in the latest consolidated financial statements and for the financial year ended 31 December 2025.

## CLEOPATRA HOSPITAL COMPANY “S.A.E.” AND ITS SUBSIDIARIES

### Notes to the interim condensed consolidated financial statements For the three months period ended 31 March 2026

(All amounts in the notes are shown in Egyptian Pounds unless otherwise stated)

#### 2. Basis of preparation (continued)

#### 2.4 Financial assets and financial liabilities

The Company holds the following financial instruments:

	Amortized cost	
	31 March 2026	31 December 2025
<b>Financial assets</b>		
Trade receivables (gross)	1,765,447,693	1,532,923,355
Debtors and other debit balances *	46,796,118	22,362,917
Cash on hand and at banks	755,366,856	550,800,902
	<b>2,567,610,667</b>	<b>2,106,087,174</b>

\* Excluding prepayments, advances to suppliers, and withholding taxes.

	Amortized cost	
	31 March 2026	31 December 2025
<b>Financial Liabilities</b>		
Loan	3,229,647,135	3,135,813,053
Creditors and other credit balances **	2,176,229,037	1,875,868,041
Lease liabilities	170,393,109	175,620,181
Bank's overdraft	513,617,643	391,325,194
	<b>6,089,886,924</b>	<b>5,578,626,469</b>

\*\* Excluding social insurance

## CLEOPATRA HOSPITAL COMPANY "S.A.E." AND ITS SUBSIDIARIES

### Notes to the interim condensed consolidated financial statements For the three months period ended 31 March 2026

(All amounts in the notes are shown in Egyptian Pounds unless otherwise stated)

### 3. Segment reporting

Business segments are reported in line with the reports provided internally to the senior management, which makes decisions related to resources allocation and evaluation of segments' performance in the Group. The senior management is represented in Group's executive management committee. The segment reports are provided to the Group based on each company as each subsidiary is considered a separate business segment.

Below is a summary of each segment, which is presented for the period ended 31 March 2026 for each segment:

	Cleopatra Hospital Company	Cairo Specialised Hospital	Nile Badrawy Hospital	Al Shrouk Hospital	CHG Medical Services	CHG Pharma for Management	CHG for Hospitals Company	ElKateb Hospital	Hospitals	Company for Medical Centers and Hospitals	Bedaya El Gedida Company	Cleopatra Heaven	Consolidation entries	Total
<b>Statement of financial position</b>														
Non-current assets	3,277,232,210	609,360,592	865,015,775	329,971,663	13,932,137	1,365,615	-	183,005,302	94,220,509	4,085,133,350	530,663,851	(1,810,607,152)	8,179,293,869	
Current assets	1,705,044,132	935,414,611	322,961,167	685,111,929	60,382,277	31,389,474	47,862,869	116,038,023	126,891,836	2,111,938,732	127,041,530	(1,564,681,614)	2,805,394,967	
<b>Total assets</b>	<b>4,982,276,342</b>	<b>1,544,775,203</b>	<b>1,187,976,942</b>	<b>1,015,083,592</b>	<b>74,314,414</b>	<b>32,755,089</b>	<b>47,862,869</b>	<b>299,043,325</b>	<b>221,112,345</b>	<b>4,297,072,082</b>	<b>657,705,381</b>	<b>(3,375,288,766)</b>	<b>10,984,688,836</b>	
Current liabilities	2,062,596,363	457,890,364	337,985,364	228,609,330	76,533,690	42,069,351	1,917,543	116,116,336	96,692,218	1,645,611,896	328,683,947	(1,569,367,423)	3,825,339,139	
Non-current liabilities	275,579,570	74,304,484	316,656,626	30,702,590	3,731,749	1,796,116	-	3,727,090	2,011,016	1,833,822,049	375,728,261	31,655,645	2,949,715,196	
<b>Total liabilities</b>	<b>2,338,175,933</b>	<b>532,194,848</b>	<b>654,642,132</b>	<b>259,311,920</b>	<b>80,265,439</b>	<b>43,865,467</b>	<b>1,917,543</b>	<b>119,843,426</b>	<b>98,703,234</b>	<b>3,479,433,945</b>	<b>704,412,208</b>	<b>(1,537,711,778)</b>	<b>6,775,064,954</b>	
<b>Statement of profit or loss:</b>														
Revenue	623,399,935	419,907,569	239,751,166	269,458,328	48,393,250	32,024,479	17,223	80,536,895	39,517,939	154,295,499	108,108,700	(42,892,982)	1,972,518,001	
Cost of obtaining revenue	(339,067,914)	(254,012,051)	(172,260,553)	(169,048,698)	(33,922,016)	(31,607,669)	-	(59,795,490)	(29,840,234)	(192,820,908)	(88,220,967)	42,666,766	(1,327,929,734)	
<b>Gross profit</b>	<b>284,332,021</b>	<b>165,895,518</b>	<b>67,490,613</b>	<b>100,409,630</b>	<b>14,471,234</b>	<b>416,810</b>	<b>17,223</b>	<b>20,741,405</b>	<b>9,677,705</b>	<b>(38,525,409)</b>	<b>19,887,733</b>	<b>(226,216)</b>	<b>644,588,267</b>	
Other income and expenses	(154,354,612)	(89,125,417)	(57,591,594)	(60,572,132)	(11,383,288)	(1,283,004)	(214,599)	(17,954,455)	(8,175,132)	(50,630,313)	(39,738,623)	(645,889)	(491,679,680)	
<b>Profit for the year</b>	<b>129,977,409</b>	<b>76,770,101</b>	<b>9,899,019</b>	<b>39,837,498</b>	<b>3,087,946</b>	<b>(866,194)</b>	<b>(197,376)</b>	<b>2,786,950</b>	<b>1,502,573</b>	<b>(89,155,722)</b>	<b>(19,850,890)</b>	<b>(872,105)</b>	<b>152,908,590</b>	
<b>Other items</b>														
Capital expenditures	44,088,675	13,626,006	35,275,685	7,990,575	196,364	-	-	987,768	365,401	305,257,923	29,174,185	-	436,962,582	
Fixed assets depreciation	15,487,818	12,248,560	12,361,955	9,035,745	529,461	23,942	-	4,697,888	1,805,902	55,674,055	4,941,729	1,585,651	118,392,706	

\* Consolidated adjustment is mainly represented by the elimination of intercompany balances, transactions and consolidation adjustments for investment in subsidiaries.

## CLEOPATRA HOSPITAL COMPANY "S.A.E." AND ITS SUBSIDIARIES

### Notes to the interim condensed consolidated financial statements For the three months period ended 31 March 2026

(All amounts in the notes are shown in Egyptian Pounds unless otherwise stated)

### 3. Segment reporting (continued)

Business segments are reported in line with the reports provided internally to senior management, which makes decisions about allocation of resources and assessment of segment performance in the Group. Senior management is represented on the Group's Executive Management Committee. Segment reporting is provided to the Group based on each company, whereas each subsidiary is considered a separate business segment.

Below is a summary of each segment, which is presented for the year ended 31 December 2025 for each segment:

	Bedaya El Gedida Company for Medical Centers and Hospitals										Total			
	Cleopatra Hospital Company	Cairo Specialised Hospital	Nile Badrawy Hospital	Al Shrouk Hospital	CHG Medical Services	CHG Pharma for Management	CHG for Hospitals	EiKatch Hospital	CHG SKY Hospital	Cleopatra Heaven		Consolidation entries		
<b>Statement of financial position</b>														
Non-current assets	3,253,157,921	608,969,751	844,331,371	331,718,222	16,012,350	1,519,064	-	184,265,267	96,178,340	3,835,639,044	496,359,524	(1,790,217,495)	7,877,933,359	
Current assets	1,356,551,148	808,183,514	290,671,928	622,985,715	54,165,435	35,968,622	48,376,245	95,842,745	109,810,819	122,123,615	133,372,986	(1,314,726,846)	2,363,325,926	
<b>Total assets</b>	<b>4,609,709,069</b>	<b>1,417,153,265</b>	<b>1,135,003,299</b>	<b>954,703,937</b>	<b>70,177,785</b>	<b>37,487,686</b>	<b>48,376,245</b>	<b>280,108,012</b>	<b>205,989,159</b>	<b>3,957,762,659</b>	<b>629,732,510</b>	<b>(3,104,944,341)</b>	<b>10,241,259,285</b>	
Current liabilities	1,817,042,206	403,380,576	357,150,981	207,287,925	65,774,140	44,884,429	2,233,543	100,056,859	82,980,883	1,240,508,340	308,073,184	(1,319,055,904)	3,310,317,162	
Non-current liabilities	294,893,610	77,962,435	254,416,527	31,481,838	13,442,616	2,847,451	-	3,638,207	2,101,739	1,810,460,460	367,319,277	32,012,420	2,890,576,580	
<b>Total liabilities</b>	<b>2,111,935,816</b>	<b>481,343,011</b>	<b>611,567,508</b>	<b>238,769,763</b>	<b>79,216,756</b>	<b>47,731,880</b>	<b>2,233,543</b>	<b>103,695,066</b>	<b>85,082,622</b>	<b>3,050,968,800</b>	<b>675,392,461</b>	<b>(1,287,043,484)</b>	<b>6,200,893,742</b>	
<b>Statement of profit or loss:</b>														
Revenue	2,461,037,749	1,579,063,693	1,056,561,565	1,074,090,828	205,154,327	117,727,831	3,789,997	350,388,230	166,098,826	-	404,518,175	(191,166,761)	7,227,264,460	
Cost of obtaining revenue	(1,280,600,614)	(988,677,445)	(714,228,174)	(666,628,996)	(137,262,594)	(114,287,800)	-	(238,794,303)	(106,481,164)	-	(312,095,386)	190,261,883	(4,368,794,593)	
<b>Gross profit</b>	<b>1,180,437,135</b>	<b>590,386,248</b>	<b>342,333,391</b>	<b>407,461,832</b>	<b>67,891,733</b>	<b>3,440,031</b>	<b>3,789,997</b>	<b>111,593,927</b>	<b>59,617,662</b>	<b>-</b>	<b>92,422,789</b>	<b>(904,878)</b>	<b>2,858,469,867</b>	
Other income and expenses	(660,423,354)	(305,568,346)	(260,196,937)	(222,568,626)	(31,152,348)	(4,912,129)	(1,834,670)	(75,720,022)	(42,498,303)	(133,926,040)	(153,020,136)	1,217,358	(1,890,603,553)	
<b>Profit for the year</b>	<b>520,013,781</b>	<b>284,817,902</b>	<b>82,136,454</b>	<b>184,893,206</b>	<b>36,739,385</b>	<b>(1,472,098)</b>	<b>1,955,327</b>	<b>35,873,905</b>	<b>17,119,359</b>	<b>(133,926,040)</b>	<b>(60,597,347)</b>	<b>312,480</b>	<b>967,866,317</b>	
<b>Other items</b>														
Capital expenditures	294,886,907	97,704,776	254,939,127	58,010,758	1,396,361	403,308	-	19,699,678	3,782,728	1,745,207,327	175,562,255	-	2,651,593,225	
Fixed assets depreciation	58,841,355	42,220,031	42,853,081	34,151,534	1,980,826	55,097	-	10,681,534	6,865,943	-	13,655,001	6,342,600	217,627,002	

\* Consolidated adjustment is mainly represented by the elimination of intercompany balances, transactions and consolidation adjustments for investment in subsidiaries.

## CLEOPATRA HOSPITAL COMPANY "S.A.E." AND ITS SUBSIDIARIES

### Notes to the interim condensed consolidated financial statements For the three months period ended 31 March 2026

(All amounts in the notes are shown in Egyptian Pounds unless otherwise stated)

#### 3. Segment reporting (continued)

Below is a summary of each segment, which is presented for the period ended 31 March 2025 for each segment:

	Cleopatra Hospital Company	Cairo Specialised Hospital	Nile Badrawy Hospital	Al Shrouk Hospital	CHG Medical Services	CHG Pharma for Pharmacy Management	CHG for Hospitals Company	ElKaateb Hospital	Centers and Hospitals	CHG SKY Hospital	Cleopatra Heaven	Consolidation entries	Total
<b>Statement of financial position</b>									Bedaya El Gedida Company for Medical Centers and Hospitals				
Non-current assets	2,664,049,077	560,705,375	672,522,013	309,962,764	18,143,810	1,690,316	-	181,551,757	99,673,460	2,503,335,048	416,344,552	(1,370,043,842)	6,057,934,330
Current assets	1,094,968,032	588,410,307	311,830,942	490,561,168	54,847,881	38,887,058	49,626,767	87,268,168	86,685,714	286,856,530	147,299,864	(515,451,241)	2,721,791,190
<b>Total assets</b>	<b>3,759,017,109</b>	<b>1,149,115,682</b>	<b>984,352,955</b>	<b>800,523,932</b>	<b>72,991,691</b>	<b>40,577,374</b>	<b>49,626,767</b>	<b>268,819,925</b>	<b>186,359,174</b>	<b>2,790,191,578</b>	<b>563,644,416</b>	<b>(1,885,495,083)</b>	<b>8,779,725,520</b>
Current liabilities	1,224,250,725	345,670,715	292,126,719	187,503,731	106,056,614	46,707,599	4,868,688	114,239,787	78,355,433	520,516,198	478,978,323	(530,464,161)	2,868,810,371
Non-current liabilities	346,081,857	77,249,807	219,700,650	32,681,410	4,540,143	1,768,694	-	4,251,827	3,592,435	1,665,495,693	72,411,647	(43,054,316)	2,470,828,479
<b>Total liabilities</b>	<b>1,570,332,582</b>	<b>422,920,522</b>	<b>511,827,369</b>	<b>220,185,141</b>	<b>110,596,757</b>	<b>48,476,293</b>	<b>4,868,688</b>	<b>118,491,614</b>	<b>81,947,868</b>	<b>2,186,011,891</b>	<b>551,389,970</b>	<b>(487,409,845)</b>	<b>5,339,638,850</b>
<b>Statement of profit or loss:</b>													
Revenue	525,216,305	364,638,856	250,517,652	248,151,629	44,919,563	28,389,441	909,787	74,785,241	33,362,826	-	84,594,444	(36,828,189)	1,618,657,555
Cost of obtaining revenue	(286,305,189)	(230,811,600)	(170,056,726)	(156,303,238)	(30,234,385)	(26,798,105)	-	(49,861,391)	(24,057,905)	-	(66,559,156)	36,594,610	(1,004,393,085)
<b>Gross profit</b>	<b>238,911,116</b>	<b>133,827,256</b>	<b>80,460,926</b>	<b>91,848,391</b>	<b>14,685,178</b>	<b>1,591,336</b>	<b>909,787</b>	<b>24,923,850</b>	<b>9,304,921</b>		<b>18,035,288</b>	<b>(233,579)</b>	<b>614,264,470</b>
Other income and expenses	(136,778,422)	(68,312,897)	(58,025,899)	(50,576,620)	(6,511,888)	(718,159)	(339,083)	(15,134,580)	(8,680,674)	(11,540,212)	(20,718,238)	(4,637,664)	(381,975,201)
<b>Profit for the year</b>	<b>102,132,694</b>	<b>65,514,359</b>	<b>22,435,027</b>	<b>41,271,771</b>	<b>8,173,290</b>	<b>873,177</b>	<b>570,704</b>	<b>9,789,270</b>	<b>624,247</b>	<b>(11,540,212)</b>	<b>(2,682,950)</b>	<b>(4,871,243)</b>	<b>232,289,270</b>
<b>Other items</b>													
Capital expenditures	76,799,599	39,305,715	42,506,643	8,534,789	173,517	53,909	-	9,412,531	319,278	412,186,851	49,012,576	-	638,305,408
Fixed assets depreciation	10,051,387	10,335,547	10,637,492	8,255,766	503,603	8,594	-	4,332,798	1,663,403	-	2,802,136	1,585,652	50,176,378

\* Consolidated adjustment is mainly represented by elimination of intercompany balances, transactions and consolidation adjustments for investment in subsidiaries.

**CLEOPATRA HOSPITAL COMPANY "S.A.E." AND ITS SUBSIDIARIES**

**Notes to the interim condensed consolidated financial statements  
For the three months period ended 31 March 2026**

(All amounts in the notes are shown in Egyptian Pounds unless otherwise stated)

**4. Fixed assets**

	Lands	Machinery, equipment and devices	Furniture	Buildings	Vehicles	Computers	Projects under construction	Total
<b>At 1 January 2025</b>								
Cost	173,240,262	1,204,328,371	213,910,044	1,035,227,517	58,744,148	188,021,707	2,768,442,562	5,641,914,611
Accumulated depreciation	-	(504,020,285)	(105,340,596)	(222,563,085)	(19,605,611)	(148,152,808)	-	(999,682,385)
<b>Net book value</b>	<b>173,240,262</b>	<b>700,308,086</b>	<b>108,569,448</b>	<b>812,664,432</b>	<b>39,138,537</b>	<b>39,868,899</b>	<b>2,768,442,562</b>	<b>4,642,232,226</b>
<b>Year ended 31 December 2025</b>								
Opening net book value	173,240,262	700,308,086	108,569,448	812,664,432	39,138,537	39,868,899	2,768,442,562	4,642,232,226
Additions	-	64,385,244	20,037,003	61,031,702	5,755,000	9,354,023	2,489,923,928	2,650,486,900
Disposals	-	(3,988,703)	(3,923,955)	(182,182)	(3,985,000)	(1,690,049)	-	(13,769,889)
Cost adjustments	-	(192,495)	358,658	-	-	(166,163)	-	-
Transfers from projects under construction	-	70,448,084	12,826,933	432,301,480	-	4,522,151	(520,098,648)	-
Depreciation for the year	-	(115,155,714)	(27,927,009)	(46,034,559)	(8,749,837)	(19,759,883)	-	(217,627,002)
Accumulated depreciation of disposal	-	3,322,276	3,373,932	177,126	3,092,956	1,634,567	-	11,600,857
Adjustments on accumulated depreciation	-	(53,520)	129,171	-	-	(75,651)	-	-
<b>Closing net book value</b>	<b>173,240,262</b>	<b>719,073,258</b>	<b>113,444,181</b>	<b>1,259,957,999</b>	<b>35,251,656</b>	<b>33,687,894</b>	<b>4,738,267,842</b>	<b>7,072,923,092</b>
<b>At 31 December 2025</b>								
Cost	173,240,262	1,334,980,501	243,208,683	1,528,378,517	60,514,148	200,041,669	4,738,267,842	8,278,631,622
Accumulated depreciation	-	(615,907,243)	(129,764,502)	(268,420,518)	(25,262,492)	(166,353,775)	-	(1,205,708,530)
<b>Net book value at 31 December 2025</b>	<b>173,240,262</b>	<b>719,073,258</b>	<b>113,444,181</b>	<b>1,259,957,999</b>	<b>35,251,656</b>	<b>33,687,894</b>	<b>4,738,267,842</b>	<b>7,072,923,092</b>
<b>At 31 March 2026</b>								
Opening net book value	173,240,262	719,073,258	113,444,181	1,259,957,999	35,251,656	33,687,894	4,738,267,842	7,072,923,092
Additions	-	4,877,525	1,298,260	-	-	9,849,921	420,936,876	436,962,582
Disposals	-	(565,959)	(138,748)	(1,355)	-	-	-	(706,062)
Transfers from projects under construction	-	630,479,876	171,474,310	3,111,026,697	4,830,000	186,387,928	(4,104,198,811)	-
Depreciation for the period	-	(45,321,469)	(12,345,449)	(42,296,564)	(2,341,177)	(16,088,047)	-	(118,392,706)
Accumulated depreciation of disposal	-	544,982	124,250	517	-	-	-	669,749
<b>Balance at 31 March 2025</b>	<b>173,240,262</b>	<b>1,309,088,213</b>	<b>273,856,804</b>	<b>4,328,687,294</b>	<b>37,740,479</b>	<b>213,837,696</b>	<b>1,055,005,907</b>	<b>7,391,456,655</b>
<b>At 31 March 2026</b>								
Cost	173,240,262	1,969,771,943	415,842,505	4,639,403,859	65,344,148	396,279,518	1,055,005,907	8,714,888,142
Accumulated depreciation	-	(660,683,730)	(141,985,701)	(310,716,565)	(27,603,669)	(182,441,822)	-	(1,323,431,487)
<b>Net book value at the period end</b>	<b>173,240,262</b>	<b>1,309,088,213</b>	<b>273,856,804</b>	<b>4,328,687,294</b>	<b>37,740,479</b>	<b>213,837,696</b>	<b>1,055,005,907</b>	<b>7,391,456,655</b>

## CLEOPATRA HOSPITAL COMPANY “S.A.E.” AND ITS SUBSIDIARIES

### Notes to the interim condensed consolidated financial statements For the three months period ended 31 March 2026

(All amounts in the notes are shown in Egyptian Pounds unless otherwise stated)

#### 5. Right-of-use assets

##### The Egyptian Standard No. (49) “Leasing Contracts” has been applied in two phases as follows:

The first stage relates to lease contracts that were subject to Law (95) for the year 1995 starting on or after 1 January 2019, which are lease contracts related to medical equipment and measured at the beginning of the contract at a value equal to the value of the lease obligations in addition to rental expenses and subsequently depreciated over the life of the lease contracts using the straight-line method.

The second phase represents lease contracts related to buildings that were subject to Law (95) for the year 1995 starting on or after 1 January 2021 and measured at a carrying amount as if the standard had been applied since inception of the lease but discounted using the lending rate to the lessee at the date of application and it is subsequently depreciated over the life of the lease using the straight-line method.

	<u>31 March 2026</u>	<u>31 December 2025</u>
<b>Machinery and equipment</b>		
Beginning balance for the period/year	8,354,866	10,470,794
Depreciation during the period/year	(528,982)	(2,115,928)
<b>Total – machinery and equipment</b>	<u>7,825,884</u>	<u>8,354,866</u>
<b>Buildings</b>		
Beginning balance for the period/year	124,566,053	65,137,373
Settlements	-	1,580,406
Additions for the period /year	411,625	88,951,146
Disposals for the period /year	-	(172,866)
Depreciation for the period /year	(7,806,229)	(30,930,006)
<b>Total</b>	<u>117,171,449</u>	<u>124,566,053</u>
	<u>124,997,333</u>	<u>132,920,919</u>

Lease payments are discounted using the interest rate implicit in the lease. If this rate cannot be determined, the lessee’s borrowing rate is used, which is the rate that the lessee shall pay to borrow the funds needed for the acquisition of an equivalent value asset in a similar economic environment with similar terms and conditions. An average interest rate of 11,5%. For finance lease contracts relating to buildings, with an interest rate of 12.15% are applied, and 16.15% for finance lease contracts relating to machinery and medical equipment, for contracts existing at the date of initial recognition upon applying the change in the standard. For new contracts, the lessee’s incremental borrowing rate is used, which represents the rate that the lessee would have to pay to borrow the funds necessary to obtain an asset of similar value in a similar economic environment, under similar terms and conditions, at the contract inception date.

## CLEOPATRA HOSPITAL COMPANY “S.A.E.” AND ITS SUBSIDIARIES

### Notes to the interim condensed consolidated financial statements For the three months period ended 31 March 2026

(All amounts in the notes are shown in Egyptian Pounds unless otherwise stated)

#### 6. Advance payments / Revenue share

	<u>31 March 2026</u>	<u>31 December 2025</u>
<b>Beginning balance</b>	<b>250,336,106</b>	-
Additions for the period /year	-	286,000,000
Used for the period / year	(360,000)	(1,440,000)
Decrease in Company’s revenue share	(8,372,146)	(34,223,894)
<b>Total</b>	<b>241,603,960</b>	<b>250,336,106</b>

#### Partnership agreement for the management and operation of Haven Medical Complex

On 6 February 2025, a partnership agreement was entered f for the management and operation of Haven Medical Complex in 6th of October City for a period of 25 years commencing from the date of obtaining the operating license between the Fund for Improving Social and Healthcare Services for Police Officers and Their Families (the “First Party”) and Cleopatra Haven Hospital S.A.E. (the “Second Party”) The key terms of the agreement are as follows:

1. The usufruct agreement for Haven Hospital dated 31 October 2022 has been mutually terminated and replaced by this agreement, which now governs the relationship between the parties in respect of the project land and the Haven Medical Complex (including Haven hospital).
2. The agreement is effective from the signing date and remains valid for 25 years from the date of obtaining the operating license, renewable for additional periods upon mutual written consent.
3. The First Party is responsible for the construction and completion of the Haven Medical Complex, including civil, structural, electrical, and mechanical works, as well as construction supervision and rectification of defects.
4. The Second Party shall continue to manage and operate Haven Hospital and shall take over the medical complex upon completion. The Second Party is responsible, at its own cost, for equipping the complex with medical and non-medical equipment, furniture, and fittings, and for operating the complex throughout the contract term, in addition to paying the agreed consideration to the First Party.
5. Upon expiry of the agreement, the Second Party shall return the medical complex, including all improvements, in good condition (subject to normal wear and tear), along with all equipment and furniture used in the operation.
6. The Second Party shall not recover the previously paid advance amount of EGP 36 million, which was paid under the prior usufruct agreement, and such amount shall neither be refunded nor offset against the annual participation fees.
7. The Second Party shall pay an amount of EGP 250 million to the First Party within 30 days from the signing date. This amount is treated as an advance payment, which is amortized against the annual participation percentages. Any unutilized balance is carried forward to subsequent financial years until fully consumed. Once the advance is fully utilized, the Second Party shall pay the full amounts due without deductions.

**CLEOPATRA HOSPITAL COMPANY “S.A.E.” AND ITS SUBSIDIARIES**

**Notes to the interim condensed consolidated financial statements  
For the three months period ended 31 March 2026**

(All amounts in the notes are shown in Egyptian Pounds unless otherwise stated)

**6. Advance payments / Revenue share (continued)**

8. The First Party is entitled to an annual return in consideration for granting the management and operation rights, calculated as a percentage of total revenues of Haven Medical Complex, based on the approved financial statements, as follows (payable only after full utilization of the advance payment):

<b>Year</b>	<b>Amount due</b>
From year 1 to year 5	8% of the total revenues of Haven Medical Complex in accordance with the approved financial statements
From year 5 to year 6	9% of the total revenues of Haven Medical Complex in accordance with the approved financial statements
For the remaining term of the contract	10% of the total revenues of Haven Medical Complex in accordance with the approved financial statements

**7. Inventory**

	<b>31 March 2026</b>	<b>31 December 2025</b>
Medical supply inventory	187,368,816	150,551,431
Medicine inventory	125,216,486	123,496,938
Hospitality inventory	7,129,378	7,120,766
Stationary inventory	3,611,540	3,570,847
Maintenance and spare parts inventory	3,386,829	2,949,398
Food and beverage inventory	1,517,462	943,204
	<b>328,230,511</b>	<b>288,632,584</b>
Less: Impairment of inventory	(10,310,857)	(7,297,580)
	<b>317,919,654</b>	<b>281,335,004</b>

Movement in the provision for inventory is as follows:

	<b>31 March 2026</b>	<b>31 December 2025</b>	<b>31 March 2025</b>
<b>Balance at the beginning of the period/ year</b>	<b>7,297,580</b>	<b>1,879,769</b>	<b>1,879,769</b>
Provisions formed during the period/ year	3,015,380	5,436,462	282,035
Provisions no longer required during the period/ year	(2,103)	(18,651)	(38,454)
<b>Balance at the end of the period/ year</b>	<b>10,310,857</b>	<b>7,297,580</b>	<b>2,123,350</b>

## CLEOPATRA HOSPITAL COMPANY “S.A.E.” AND ITS SUBSIDIARIES

### Notes to the interim condensed consolidated financial statements For the three months period ended 31 March 2026

(All amounts in the notes are shown in Egyptian Pounds unless otherwise stated)

#### 8. Trade receivables

	<b>31 March 2026</b>	<b>31 December 2025</b>
Trade receivables	1,685,173,164	1,491,005,143
Inpatients	80,274,529	41,918,214
	<b>1,765,447,693</b>	<b>1,532,923,357</b>
Less: Expected credit losses in trade receivables	(319,994,906)	(291,467,341)
	<b>1,445,452,787</b>	<b>1,241,456,016</b>

Revenue from inpatients includes revenue that has not been billed at the financial position date for their residency while the medical services' procedures have not been completed. This revenue is calculated after deducting the amounts collected in advance during their residency.

The Group applies the EAS (47) simplified approach for measuring expected credit losses which uses a lifetime expected loss allowance for all trade receivables.

The expected loss rates are based on the profiles of customers' payments over a period of 36 months before the date of the statement of financial position and corresponding historical credit losses experienced within this period. The historical loss rates are adjusted to reflect current and forward-looking information on macroeconomic factors affecting the ability of the customers to settle the debit balances. The Group has identified the GDP and the unemployment rate in countries in which it sells its goods and services to be the most relevant factor, and accordingly adjusts the historical loss rates based on expected changes in these factors.

Credit loss provision for trade receivables is determined according to the provision matrix presented in the table below. The provision matrix is based on the number of days an asset is past due.

	<b>31 March 2026</b>			
	<b>Loss Rate</b>	<b>Gross carrying amount</b>	<b>Lifetime ECL</b>	<b>Net carrying value</b>
<b>Trade receivables</b>				
- Current until less than 30 days overdue	%0.4	967,404,231	3,772,016	963,632,214
- 31 to 60 days overdue	%2	200,787,220	4,300,974	196,486,246
- 61 to 90 days overdue	%5	96,169,276	5,094,512	91,074,764
- 91 to 120 days overdue	%10	56,292,688	5,559,115	50,733,573
- 121 to 360 days overdue	%30	174,160,030	51,707,187	122,452,843
- 361 to 720 days overdue	%50	42,519,908	21,446,762	21,073,146
- More than 720 days	%100	228,114,340	228,114,340	-
		<b>1,765,447,693</b>	<b>319,994,906</b>	<b>1,445,452,787</b>
	<b>31 December 2025</b>			
	<b>Loss Rate</b>	<b>Gross carrying amount</b>	<b>Lifetime ECL</b>	<b>Net carrying value</b>
<b>Trade receivables</b>				
- Current until less than 30 days overdue	0.4%	863,374,459	2,901,407	860,473,052
- 31 to 60 days overdue	2%	132,802,207	3,247,257	129,554,949
- 61 to 90 days overdue	5%	87,529,441	4,673,154	82,856,287
- 91 to 120 days overdue	10%	65,636,856	6,849,592	58,787,264
- 121 to 360 days overdue	29%	139,273,913	40,757,118	98,516,795
- 361 to 720 days overdue	59%	27,510,946	16,243,277	11,267,669
- More than 720 days	100%	216,795,536	216,795,536	-
		<b>1,532,923,357</b>	<b>291,467,341</b>	<b>1,241,456,016</b>

## CLEOPATRA HOSPITAL COMPANY “S.A.E.” AND ITS SUBSIDIARIES

### Notes to the interim condensed consolidated financial statements For the three months period ended 31 March 2026

(All amounts in the notes are shown in Egyptian Pounds unless otherwise stated)

#### 8. Trade receivables (continued)

The movement in the impairment consists of the following:

	<b>31 March 2026</b>	<b>31 December 2025</b>	<b>31 March 2025</b>
Balance at the beginning of the period / year	291,467,341	182,171,926	182,171,926
Formed during the period / year	34,352,223	122,071,591	32,871,416
No longer required during the period / year	<u>(5,824,658)</u>	<u>(12,776,176)</u>	-
	<b><u>319,994,906</u></b>	<b><u>291,467,341</u></b>	<b><u>215,043,342</u></b>

#### 9. Debtors and other debit balances

	<b>31 March 2026</b>	<b>31 December 2025</b>
Advances to suppliers	146,135,224	193,659,419
Prepaid expenses	80,526,539	38,691,787
Withholding taxes	18,986,875	17,824,643
Deposits with others	10,917,280	10,842,280
Employee's custodies	1,270,779	411,001
Accrued income	253,558	465,131
Other debtors	<u>34,354,501</u>	<u>31,099,278</u>
	<b><u>292,444,756</u></b>	<b><u>292,993,539</u></b>
Less: ECL of other debit balances during the period / year	<u>(1,474)</u>	<u>(1,474)</u>
	<b><u>292,443,282</u></b>	<b><u>292,992,065</u></b>

The movement of the provision for ECL during the period / year is as follows:

	<b>31 March 2026</b>	<b>31 December 2025</b>	<b>31 March 2025</b>
Balance at 1 January	<u>1,474</u>	<u>1,474</u>	<u>1,474</u>
	<b><u>1,474</u></b>	<b><u>1,474</u></b>	<b><u>1,474</u></b>

## CLEOPATRA HOSPITAL COMPANY “S.A.E.” AND ITS SUBSIDIARIES

### Notes to the interim condensed consolidated financial statements For the three months period ended 31 March 2026

(All amounts in the notes are shown in Egyptian Pounds unless otherwise stated)

#### 10. Cash on hand and at banks

	<b>31 March 2026</b>	<b>31 December 2025</b>
Current accounts	653,989,121	461,316,153
Time deposit	101,377,735	89,484,749
Cash on hand	4,135,870	3,782,317
Deduct: Cash and cash equivalents impairment	<u>(9,923,482)</u>	<u>(7,040,378)</u>
	<b><u>749,579,244</u></b>	<b><u>547,542,841</u></b>

- The time deposits item includes an amount EGP 101,377,735 on 31 March 2026 (31 December 2025: EGP 89,484,749) are denominated in local banks in US dollars and are payable within one month from the date of deposit and are subject to a fixed annual return from 3.75%
- Current accounts deposited in Egyptian Pounds are subject to a fixed annual rate from 15% to 16% (2025: from 15% to 16%)

Movement in the impairment is as follows:

	<b>31 March 2026</b>	<b>31 December 2025</b>	<b>31 March 2025</b>
Balance at the beginning of the period / year	7,040,378	4,597,154	4,597,154
Formed during the period / year	3,159,992	4,395,459	1,510,208
No longer required	<u>(276,888)</u>	<u>(1,952,235)</u>	-
<b>Ending balance at the ending of the period / year</b>	<b><u>9,923,482</u></b>	<b><u>7,040,378</u></b>	<b><u>6,107,362</u></b>

For the purpose of preparation of the cash flow statements, cash and cash equivalents consist of:

	<b>31 March 2026</b>	<b>31 March 2025</b>
Cash and bank balances	759,502,726	700,694,012
<b>Total</b>	<b><u>759,502,726</u></b>	<b><u>700,694,012</u></b>

Time deposits are held with banks and displayed as cash and cash equivalents if they mature for three months or less from the date of deposit and are payable with 24 hours' notice without loss of interest. Treasury bills classified under cash and cash equivalents have original maturities of no more than three months from the date of acquisition. These instruments are readily convertible into known amounts of cash and are subject to an insignificant risk of changes in value.

The Company's cash and bank balances are held at reputable financial institutions with credit ratings from Moody's and Standard & Poor's from B3 up to CAA1.

## CLEOPATRA HOSPITAL COMPANY “S.A.E.” AND ITS SUBSIDIARIES

### Notes to the interim condensed consolidated financial statements For the three months period ended 31 March 2026

(All amounts in the notes are shown in Egyptian Pounds unless otherwise stated)

#### 11. Non-controlling interests

	Capital	Reserves	Retained earnings	NCI share in acquisition adjustments	Total
<b>Balance at 1 January 2025</b>	33,654,441	11,590,275	232,843,698	120,184	278,208,598
Employee profit share	-	-	(4,166,834)	-	(4,166,834)
Legal reserve	-	1,818	-	-	1,818
Comprehensive income for the year	-	-	143,984,628	-	143,984,628
<b>Balance at 31 December 2025</b>	<b>33,654,441</b>	<b>11,592,093</b>	<b>372,661,492</b>	<b>120,184</b>	<b>418,028,210</b>
<b>Balance at 1 January 2026</b>	33,654,441	11,592,093	372,661,492	120,184	418,028,210
Comprehensive income for the year	-	-	34,813,790	-	34,813,790
<b>Balance at 31 March 2026</b>	<b>33,654,441</b>	<b>11,592,093</b>	<b>407,475,282</b>	<b>120,184</b>	<b>452,842,000</b>

#### 12. Loans

31 March 2026	Current	Non-current	Total
Loans	457,951,145	2,771,695,990	3,229,647,135
<b>Total</b>	<b>457,951,145</b>	<b>2,771,695,990</b>	<b>3,229,647,135</b>
31 December 2025	Current	Non-current	Total
Loans	451,063,593	2,684,749,460	3,135,813,053
<b>Total</b>	<b>451,063,593</b>	<b>2,684,749,460</b>	<b>3,135,813,053</b>

#### KFH Loan

- On 27 October 2021, Cleopatra Hospital Company signed a contract for a medium term loan with Kuwait Finance House, with a total amount of EGP 145 million, with a return of 0,65%, in addition to the lending rate announced by the Central Bank of Egypt.
- On 10 August 2022, Cleopatra Hospital Company, Nile Badrawy Hospital Company, and Cairo Specialised Hospital Company signed an appendix to the loan contract from Kuwait Finance House. Following are the most significant contracting terms.
- Increasing the financing amount to EGP 285 million, and it will be divided among the companies as follows:

Cleopatra Hospital Company	EGP 45 million
Cairo Specialised Hospital	EGP 90 million
Nile Badrawy Hospital Company	EGP 150 million

## CLEOPATRA HOSPITAL COMPANY “S.A.E.” AND ITS SUBSIDIARIES

### Notes to the interim condensed consolidated financial statements For the three months period ended 31 March 2026

(All amounts in the notes are shown in Egyptian Pounds unless otherwise stated)

---

#### 12. Loans (continued)

##### KFH Loan (continued)

- On 10 May 2023, the financing amount was redistributed among the companies as follows, provided that the maximum available financing limit is EGP 340 million, and the mentioned amount is not exceeded at any time throughout the contract term.

Cleopatra Hospital Company	EGP 100 million
Cairo Specialised Hospital	EGP 90 million
Nile Badrawy Hospital Company	EGP 150 million

On 18 January 2024, the financing amount was redivided among the companies as follows, provided that the maximum amount of financing available amounts to EGP 740 million, and the aforementioned amount shall not be exceeded at any time throughout the contract period.

Cleopatra Hospital Company	EGP 500 million
Cairo Specialized Hospital Company	EGP 90 million
Nile Badrawy Hospital Company	EGP 150 million

On 17 April 2024, the financing amount was redivided among the companies as follows, provided that the maximum amount of financing available amounts to EGP 740 million, and the aforementioned amount shall not be exceeded at any time throughout the contract period.

Cleopatra Hospital Company	EGP 400 million
Cairo Specialized Hospital Company	EGP 90 million
Nile Badrawy Hospital Company	EGP 250 million

- The purpose of the loan is to finance and/or refinance the capital needs and renovate the Group's specialized hospitals starting from 2021, including medical equipment, medical beds, medical and non-medical furniture, as well as internal development of movables (final finishes, electromechanical equipment and power station).
- This contract shall take effect for a period of six years and six months from the date of signing the finance contract on 27 October 2021, with the Group being granted availability period of a maximum of one year and six months ending on 31 December 2023, and a grace period (applied to payment of the asset) of one year and six months ending on 31 January 2024. In the event that the entire financing amount is not withdrawn during the aforementioned availability period, the unwithdrawn portion shall be automatically cancelled and the bank is not obligated to lend the Group any other amounts other than what has been withdrawn from the financing amount.
- Cleopatra Hospital company is committed to pay total amount of 397,500,000 EGP on 20 Quarterly installments where first trench with amount of 95,500,000 to be paid starting from January 2024 and the second trench amounted to 300,000,000 EGP to be paid starting from October 2025 and it ends in July 2030.:
- Cairo specialized hospital company is committed to pay total amount of 89.543.425 EGP on 20 Quarterly installments starting from January 2024 and it ends in October 2028.  
Nile Badrawi Hospital company is committed to pay total amount of 235,562,038 EGP on 20 Quarterly installments where first trench with amount of 142,572,737 to be paid starting from January 2024 and the second trench amounted to 92,989,301 EGP to be paid starting from October 2025 and it ends in July 2030.

## CLEOPATRA HOSPITAL COMPANY “S.A.E.” AND ITS SUBSIDIARIES

### Notes to the interim condensed consolidated financial statements For the three months period ended 31 March 2026

(All amounts in the notes are shown in Egyptian Pounds unless otherwise stated)

---

#### 12. Loans (continued)

##### KFH Loan (Nile Badrawi Hospital)

- On October 7, 2025, Nile Badrawi Hospital Company entered into a medium-term loan agreement with Kuwait Finance House (KFH) for a total facility amount of EGP 140 million. The primary objective of this facility is to finance the investment costs associated with the construction of the Nile Badrawi Hospital clinics. The loan carries a floating interest rate consisting of the Central Bank of Egypt (CBE) lending rate plus a margin of 0.8% in addition to the lending rate announced by the Central Bank.
- The loan facility has a total tenor of six years and six months commencing from the signing date. This includes an availability and drawdown period of a maximum of eighteen months (one year and six months). Following the lapse of the availability period, any undrawn portion of the facility shall be automatically cancelled, and the Bank shall have no further obligation to extend any additional credit beyond the amounts already disbursed
- On December 17, 2025, an amendment to the original loan agreement was executed. Under this amendment, an amount of EGP 60 million from the total facility was reallocated for the acquisition of the basement, ground floor, and mezzanine of Building No. 33, located adjacent to Nile Badrawi Hospital
- As of March 31, 2026, the total amount drawn down from the facility amounted to EGP 124,317,020.

##### Financial ratios

According to the contract terms, the companies shall achieve the following financial ratios:

- The financial leverage of the company shall not exceed 1,6
- Debt service rate shall not fall below 1.
- Liquidity rate shall not fall below 1.

Loans include specific covenants. A future breach of these covenants may lead to renegotiation. The covenants are monitored by management, in case of potential breach, actions are taken by management to ensure compliance. Financial ratios are calculated starting from 31 December 2026, and there are no outstanding overdue balances.

##### CIB Loan (CHG Sky Company)

- On 5 June 2023, CHG Sky Hospital Company signed a contract for a medium term loan with Commercial International Bank, with a total amount of EGP 1,339,573,000, with a return of 0,05% in addition to the lending rate announced by the Central Bank of Egypt for the first 9 months and then 0,09% in addition to the lending rate announced by the Central Bank of Egypt from the tenth month till the end of loan term.
- The purpose of the loan is to finance the capital needs to finalize the company’s hospitals starting, including medical equipment, medical beds, medical and non-medical furniture, as well as internal development of movables (final finishes, electromechanical equipment and power station).
- This contract shall take effect for a period of nine years and six months from the date of signing the finance contract on 5 June 2023, with the Group being granted availability period of a maximum of two years and six months ended in 31 December 2025, and a grace period (applied to payment of the asset) ending on 30 June 2026. In the event that the entire financing amount is not withdrawn during the aforementioned availability period, the unwithdrawn portion shall be automatically cancelled and the bank is not obligated to lend the Group any other amounts other than what has been withdrawn from the financing amount.

## CLEOPATRA HOSPITAL COMPANY “S.A.E.” AND ITS SUBSIDIARIES

### Notes to the interim condensed consolidated financial statements For the three months period ended 31 March 2026

(All amounts in the notes are shown in Egyptian Pounds unless otherwise stated)

#### 12. Loans (continued)

- On October 10, 2024, the credit limit was increased to EGP 1,897,000,000 with all other contract terms remaining unchanged.
- On July 31, 2025, an addendum to the loan agreement was signed, increasing the credit limit to EGP 2,194,600,000 (only two billion, one hundred and ninety-four million, six hundred thousand Egyptian pounds). The repayment schedule was changed to 27 quarterly installments, starting on September 30, 2026, and ending on December 31, 2032.

#### Financial ratios

According to the contract terms, the Company shall achieve the following financial ratios:

- The financial leverage of the Group shall be as follows:

<u>2026</u>	<u>2027</u>	<u>2028</u>	<u>2029</u>	<u>2030</u>	<u>2031</u>	<u>2032</u>
5.18	2.85	1.98	1.34	0.94	0.65	0.46

- Debt service rate shall not fall below 1.
- CAPEX should not exceed the following

<u>2026</u>	<u>2027</u>	<u>2028</u>	<u>2029</u>	<u>2030</u>	<u>2031</u>	<u>2032</u>
6,838,000	8,117,000	9,404,000	10,663,000	12,252,000	13,960,000	17,291,000
EGP	EGP	EGP	EGP	EGP	EGP	EGP

As a guarantee and security for the repayment of the financing granted by the bank to the company under this contract, in addition to interest, commissions, expenses, fees, and related charges, the company undertakes to provide the bank with a joint guarantee issued by Cleopatra Hospital Company LLC, Commercial Registration No. 199393, issued by the Cairo Investment Commercial Registry Office, guaranteeing the company's repayment of the financing amount, including principal, interest, commissions, expenses, and any other amounts due under the contract.

#### **Compliance with Financial Covenants**

Loans include certain commitments. Failure to meet these commitments in the future may lead to renegotiation. Management monitors these commitments, and in the event of a potential breach, it takes the necessary measures to ensure compliance. Financial ratios are tested as of December 31, 2026, and there are no outstanding payments.

#### Banque Misr - Cleopatra Haven Company S.A.E

- On 13 November 2024, Cleopatra Heavens Company (a subsidiary) entered into a medium-term loan agreement for a total amount of EGP 190,500,000. The maximum amount allocated for capital expansion financing is divided into two tranches: a first tranche of EGP 163,000,000 for capital expansion financing and a second tranche of EGP 27,500,000 for financing the reimbursement of amounts disbursed as part of the total investment cost before the first withdrawal.
- The purpose of the loan is to finance the Company's capital expansion projects, with an interest rate of 0.65% plus the lending corridor rate announced by the Central Bank of Egypt. The loan shall be repaid over 20 equal quarterly instalments, The loan term is 7 years, including the grace period.

## CLEOPATRA HOSPITAL COMPANY “S.A.E.” AND ITS SUBSIDIARIES

### Notes to the interim condensed consolidated financial statements For the three months period ended 31 March 2026

(All amounts in the notes are shown in Egyptian Pounds unless otherwise stated)

---

#### 12. Loans (continued)

##### **Banque Misr - Cleopatra Haven Company S.A.E (continued)**

- On 27 February 2025, Cleopatra Heavens Company (a subsidiary) entered into a medium-term loan agreement for a total amount of EGP 238,000,000 (only two hundred and thirty-eight million Egyptian pounds).
- The purpose of the loan is to finance the advance payment related to the management and operation partnership agreement of the Heavens Medical Complex.
- The loan carries an interest rate of 0.65% plus the lending corridor rate announced by the Central Bank of Egypt, and it shall be repaid over 20 equal quarterly instalments, The loan term is 7 years, including the grace period.
- As a guarantee and security for the repayment of the financing granted by the bank to the company under this contract, in addition to interest, commissions, expenses, fees, and related charges, the company undertakes to provide the bank with a joint guarantee issued by Cleopatra Hospital Company LLC, Commercial Registration No. 199393, issued by the Cairo Investment Commercial Registry Office, guaranteeing the company's repayment of the financing amount, including principal, interest, commissions, expenses, and any other amounts due under the contract.

##### **Financial ratios**

According to the contract terms, the companies shall achieve the following financial ratios:

- The financial leverage of the company shall not exceed 2
- Debt service rate shall not fall below 1.
- Liquidity rate shall not fall below 1.

##### **Compliance with Financial Covenants**

Loans include certain commitments. Failure to meet these commitments in the future may lead to renegotiation. Management monitors these commitments, and in the event of a potential breach, it takes the necessary measures to ensure compliance. Financial ratios are tested as of December 31, 2026, and there are no outstanding payments.

#### 13. Trade and other payables

	<b>31 March 2026</b>	<b>31 December 2025</b>
Accrued expenses	968,829,729	799,793,657
Trade and other payables	953,593,492	830,322,991
Social insurance	24,734,377	28,282,157
Other creditors	278,540,193	274,033,547
	<b><u>2,225,697,791</u></b>	<b><u>1,932,432,352</u></b>

**CLEOPATRA HOSPITAL COMPANY “S.A.E.” AND ITS SUBSIDIARIES**

**Notes to the interim condensed consolidated financial statements  
For the three months period ended 31 March 2026**

(All amounts in the notes are shown in Egyptian Pounds unless otherwise stated)

**14. Lease liabilities**

The lease liabilities represent the present value of the lease obligations related to medical equipment (first stage - Note 9) entered by one of the group companies and lease contracts for buildings (second stage). It was measured at the present value of the contractual lease payments discounted at an implied rate of return in the range between 11.15% and 16.65%.

	<b>31 March 2026</b>	<b>31 December 2025</b>
<b>Undiscounted</b>		
During the year	60,687,217	53,418,784
More than a year	314,684,102	326,843,506
	<b>375,371,319</b>	<b>380,262,290</b>
<b>The present value of the lease obligations is as follows:</b>		
During the year	60,687,217	53,418,784
More than a year	109,705,892	122,201,397
<b>Balance</b>	<b>170,393,109</b>	<b>175,620,181</b>
	<b>31 March 2026</b>	<b>31 December 2025</b>
<b>Lease Liabilities were presented as follows:</b>		
Lease liabilities shown as at 31 December 2025	175,620,181	109,216,063
Adjustments during the period /year	-	1,606,094
<b>Add:</b> Additions during the period /year	411,626	88,951,147
<b>Add:</b> Interest formed during the period /year	9,105,834	32,971,514
<b>Deduct:</b> Disposals during the period / year	-	(715,228)
<b>Deduct:</b> Payments during the period / year	(14,744,532)	(56,409,409)
<b>Lease liabilities at 31 March 2026</b>	<b>170,393,109</b>	<b>175,620,181</b>

## CLEOPATRA HOSPITAL COMPANY “S.A.E.” AND ITS SUBSIDIARIES

### Notes to the interim condensed consolidated financial statements For the three months period ended 31 March 2026

(All amounts in the notes are shown in Egyptian Pounds unless otherwise stated)

#### 15. Revenue

	<b>31 March 2026</b>	<b>31 March 2025</b>
Accommodation and medical supervision revenue	463,877,191	391,721,349
Surgeries revenue	331,691,861	292,470,031
Laboratories revenue	224,597,977	164,846,015
Outpatient clinics revenue	161,991,535	144,746,968
Service charge revenue	152,119,943	126,910,635
Radiology revenue	151,606,790	112,898,593
Cardiac catheterization revenue	143,303,357	112,689,971
Pharmacy revenue	127,307,684	104,845,995
Emergency revenue	72,463,070	58,762,509
Physiotherapy revenue	55,496,329	39,352,329
Cardiac tests revenue	23,694,677	16,898,729
Endoscopy revenues	18,028,121	14,905,044
Revenues of oncology centre	17,814,517	10,610,464
Dentistry revenue	6,839,665	4,809,933
Other departments revenues	21,685,284	22,188,990
	<b><u>1,972,518,001</u></b>	<b><u>1,618,657,555</u></b>

\* “Service charge” does not represent a separate performance obligation but is a surcharge at a fixed percentage rate applied to all revenue streams except for sale of medicines.

All types of revenue are recognized at a point in time except accommodation and medical supervision are recognized over time, as shown:

	<b>31 March 2026</b>	<b>31 March 2025</b>
At a point in time	1,508,640,810	1,226,936,206
Over time -Accommodation and medical supervision revenue	463,877,191	391,721,349
	<b><u>1,972,518,001</u></b>	<b><u>1,618,657,555</u></b>

## CLEOPATRA HOSPITAL COMPANY “S.A.E.” AND ITS SUBSIDIARIES

### Notes to the interim condensed consolidated financial statements For the three months period ended 31 March 2026

(All amounts in the notes are shown in Egyptian Pounds unless otherwise stated)

#### 16. Cost of revenue

	<b>31 March 2026</b>	<b>31 March 2025</b>
Medical and pharmaceutical supplies	423,197,229	379,994,105
Salaries, wages and benefits	351,097,600	248,206,848
Doctors' fees	247,169,816	195,921,365
Fixed assets depreciation	96,909,590	42,892,904
Maintenance, spare parts and energy expenses	67,213,193	54,640,167
Services from others	50,509,225	27,994,651
Consumables costs	36,575,613	26,578,497
Rents	12,383,913	7,371,645
Leased assets depreciation	5,868,481	6,272,375
Advance Payments / Revenue Share amortization	360,000	-
Other expenses	36,645,074	14,520,528
	<b><u>1,327,929,734</u></b>	<b><u>1,004,393,085</u></b>

#### 17. General and administrative expenses

	<b>31 March 2026</b>	<b>31 March 2025</b>
Salaries, wages and benefits	159,634,637	130,349,359
Services from others	29,510,301	19,955,117
Fixed assets depreciation	21,483,116	7,283,474
Professional and consulting fees	13,457,303	10,779,974
Maintenance, spare parts and energy expenses	6,353,021	4,062,874
Right of use assets depreciation	2,466,730	2,392,856
Consumables costs	2,059,599	1,602,214
Intangible assets amortization	517,321	517,321
Other expenses	91,567,313	51,377,931
	<b><u>327,049,341</u></b>	<b><u>228,321,120</u></b>

#### 18. Net impairment losses on financial assets

	<b>31 March 2026</b>	<b>31 March 2025</b>
ECL in trade receivables	28,527,564	32,871,416
ECL in cash no longer required	2,883,103	1,510,208
	<b><u>31,410,667</u></b>	<b><u>34,381,624</u></b>

## CLEOPATRA HOSPITAL COMPANY “S.A.E.” AND ITS SUBSIDIARIES

### Notes to the interim condensed consolidated financial statements For the three months period ended 31 March 2026

(All amounts in the notes are shown in Egyptian Pounds unless otherwise stated)

#### 19. Earnings per share

The basic share of the profit for the period /year is calculated by dividing the net profit for the period attributable to the parent company’s shareholders by the weighted average number of shares outstanding during the period after excluding the distribution of employee dividends.

	<b>31 March 2026</b>	<b>31 March 2025</b>
Profit for the period	152,908,590	232,289,270
(Less) Dividends for employees and the board of directors	<u>(34,813,790)</u>	<u>(31,708,796)</u>
	<b>118,094,800</b>	<b>200,580,474</b>
The weighted average number of ordinary shares for basic earnings per share purposes	1,447,151,301	1,441,509,083
The weighted average number of ordinary shares for the purpose of the ESOP	<u>2,298,783</u>	<u>2,298,783</u>
Weighted average number of ordinary shares for diluted earnings per share purposes	<b><u>1,449,450,084</u></b>	<b><u>1,443,807,866</u></b>
<b>Earnings per share - Basic</b>	<b>0.08</b>	<b>0.14</b>
<b>Earnings per share - Diluted</b>	<b><u>0.08</u></b>	<b><u>0.14</u></b>

The weighted average number of shares is adjusted to take into account the shares held under the bonus and incentive scheme for employees, directors and executive board members.

#### 20. Commitments

##### Capital commitments:

Capital commitments at the end of the financial period. which are not yet due, amounted to EGP 653,960,440 (31 December 2025: EGP 151,017,672), which represent the capital commitments to purchase of fixed assets and projects under constructions.

## CLEOPATRA HOSPITAL COMPANY “S.A.E.” AND ITS SUBSIDIARIES

### Notes to the interim condensed consolidated financial statements For the three months period ended 31 March 2026

(All amounts in the notes are shown in Egyptian Pounds unless otherwise stated)

#### 21. Significant and Subsequent events

##### 21.1 A settlement agreement regarding the land of the Nile Badrawi Hospital

On 13 February 2020, Cleopatra Hospital Company, the General Authority for River Transportation, the Nile Badrawi Hospital, and the inheritors of the Engineer Hassan Badrawy signed a comprehensive and final settlement agreement, according to which it was agreed to resolve, settle, and end all disputes and claims related to the land on which the Nile Badrawy Hospital was built. The total settlement amounted to EGP 36 million, noting that part of the settlement falls within the limits of the amounts deducted from the selling price of Nile Badrawy Hospital shares in favor of Cleopatra Hospital. It has been agreed upon a waiver of disputes between the General Authority for River Transportation Company and the Nile Badrawy Hospital that each of them raises concerning the land subject to settlement. On 31 March 2021, the Administrative Court issued a ruling that the case was accepted in form and rejected in substance. Cairo Governorate and the Nile Badrawy Hospital appealed the aforementioned ruling before the Supreme Administrative Court, and a hearing was determined on 21 September 2022, for both parties to submit settlement contracts executed between the parties. The consideration of the appeal has been deferred to a hearing on 7 February 2024, to take intervention procedures of the heirs of the late Hassan Badrawi, and to review notes for whomever wants. The appeal has been postponed until response the defence memorandum. It was postponed to 31 August 2026 to resubmit the settlement agreement.

##### 21.2 Right of use, management and operation contract for CHG Sky Hospital LLC

On December 29, 2021, an agreement was signed between the Housing and Social Services Fund for Petroleum Sector Workers, the Egyptian Natural Gas Company (GASCO) “S.A.E.” and the Egyptian Natural Gas Distribution Company for Cities (Town Gas) “S.A.E.” as the first party, and CHG Hospitals Company “S.A.E.” as the second party, to grant the right to use, manage, and operate Sky Hospital for a period of twenty-seven calendar years starting from the date of signing the agreement, provided that the second party completes all construction, electromechanical, and interior finishing works, and equips the hospital with the medical and non-medical equipment necessary to operate the hospital at its own expense. The hospital will be fully delivered, including all equipment and supplies, to the first party immediately upon the expiration of the agreement.

The first party shall receive, in return for granting the second party the right to benefit from, manage and operate Sky Hospital, a return for each fiscal year as follows:

Year	Amount due
First and second year of operation	2% of total annual revenue as shown in the approved financial statements
Starting from the third year till the sixth year of operation	3% of total annual revenue as shown in the approved financial statements
Starting from the seventh year till the end of the agreement	4% of total annual revenue as shown in the approved financial statements

During the year 2022, a transfer agreement was signed between CHG Hospitals LLC and CHG Sky Hospital LLC, and with the approval of all other parties, all terms, conditions, obligations and rights required by the agreement are transferred from CHG Hospitals LLC to CHG Sky Hospital LLC.

##### 21.3 Impact of Military Conflict

On 28 February 2026, the United States and Israel entered into a direct military confrontation with Iran. This conflict has also resulted in military engagements involving certain Gulf countries. These events are expected to have a significant economic impact on the global economy, particularly in the Middle East region. Management is closely monitoring ongoing developments to assess the potential impact of these events on the Company.